Arrowhead Pharmaceuticals Accounts Payable

Arrowhead Pharmaceuticals's accounts payable stands at $28M as of June 2026. That compares with $33M in the prior-year period — down 16.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Arrowhead Pharmaceuticals reported $28M in accounts payable versus $33M a year earlier — a 16.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $33M in the prior-year period — down 16.0% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Arrowhead Pharmaceuticals's accounts payable evolved across reporting periods, while the comparison chart places ARWR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Arrowhead Pharmaceuticals's reading of $28M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.